Torsdag 14 Augusti | 10:16:28 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2026-02-25 08:00 Bokslutskommuniké 2025
2025-11-26 08:00 Kvartalsrapport 2025-Q3
2025-08-07 - Kvartalsrapport 2025-Q2
2025-05-21 - X-dag ordinarie utdelning MODTX 0.00 SEK
2025-05-20 - Årsstämma
2025-05-14 - Kvartalsrapport 2025-Q1
2025-02-20 - Bokslutskommuniké 2024
2024-11-20 - Kvartalsrapport 2024-Q3
2024-08-23 - Kvartalsrapport 2024-Q2
2024-05-20 - X-dag ordinarie utdelning MODTX 0.00 SEK
2024-05-17 - Årsstämma
2024-05-14 - Kvartalsrapport 2024-Q1
2024-02-21 - Bokslutskommuniké 2023
2023-11-08 - Kvartalsrapport 2023-Q3
2023-08-23 - Kvartalsrapport 2023-Q2
2023-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2023-05-11 - Årsstämma
2023-05-09 - Kvartalsrapport 2023-Q1
2023-02-22 - Bokslutskommuniké 2022
2022-11-22 - Kvartalsrapport 2022-Q3
2022-08-23 - Kvartalsrapport 2022-Q2
2022-05-16 - Kvartalsrapport 2022-Q1
2022-05-12 - X-dag ordinarie utdelning MODTX 0.00 SEK
2022-05-11 - Årsstämma
2022-02-22 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-19 - Kvartalsrapport 2021-Q2
2021-05-06 - Kvartalsrapport 2021-Q1

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Modus Therapeutics är verksamt inom bioteknik. Produktportföljen är bred och inkluderar exempelvis sevuparin. Bolagets fokus är att utveckla sevuparin för patienter med sepsis / septisk chock, ett allvarligt och ofta dödligt tillstånd. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten med tillhörande forskning drivs med störst närvaro inom Sverige.
2025-08-11 11:10:00

THIS PRESS RELEASE MAY NOT BE PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SOUTH AFRICA, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, UNITED STATES OR ANY OTHER JURISDICTION WHERE SUCH ACTION IS SUBJECT TO LEGAL RESTRICTIONS IN WHOLE OR IN PART. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO ACQUIRE SECURITIES IN MODUS THERAPEUTICS HOLDING AB. SEE ALSO THE "IMPORTANT INFORMATION" SECTION BELOW.

The Board of Directors of Modus Therapeutics Holding AB ("Modus" or the "Company") has, in connection with the rights issue of units announced on June 26, 2025 (the “Rights Issue"), prepared a Swedish language EU Growth Prospectus (the “Prospectus") which today has been approved and registered by the Swedish Financial Supervisory Authority.

Publication of Prospectus
The Prospectus has been prepared in connection with the Rights Issue and has today, on August 11, 2025, been approved and registered with the Swedish Financial Supervisory Authority. The Prospectus, containing complete terms and instructions, as well as subscription forms, is available on the Company's website (www.modustx.com) and on the website of Bergs Securities (www.bergssecurities.se). The Prospectus will also be available on the website of the Swedish Financial Supervisory Authority (www.fi.se).

Summary of the Rights Issue

  • One (1) existing share in the Company on the record date, which was on August 8, 2025, entitles to one (1) unit right. Four (4) unit rights entitle the holder to subscribe for one (1) unit consisting of nine (9) shares, three (3) warrants of series TO 2026 and four (4) warrants of series TO 2030
  • The subscription price is SEK 3.15 per unit, corresponding to SEK 0.35 per new share. The warrants are issued free of charge
  • Trading in unit rights will take place during the period from August 12 – August 21, 2025
  • The subscription period runs from August 12 – August 26, 2025

The Rights Issue is fully covered by subscription commitments and guarantee undertakings. Neither subscription commitments nor guarantee undertakings are secured by bank guarantees, blocked funds, pledged assets or similar. For further information about the Rights Issue, please refer to the published Prospectus.

Advisors
Bergs Securities is sole manager and bookrunner and Advokatfirman Vinge is legal advisor to Modus in connection with the Rights Issue.